Skip to content

Burst Suppression Anesthesia for Treatment of Severe Depression

Burst Suppression Anesthesia for Treatment of Severe Depression

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02935647
Enrollment
11
Registered
2016-10-17
Start date
2016-10-01
Completion date
2018-09-30
Last updated
2021-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

This study is designed to determine if the antidepressant effects of deep anesthesia via propofol are related to EEG burst suppression.

Detailed description

Ten individuals with treatment resistant major depressive disorder will undergo 10 treatments of deep anesthesia via propofol over a 3-week period. Depression will be evaluated before and after treatment.

Interventions

Sponsors

University of Utah
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* • Diagnosis of Major Depressive Disorder (MDD) or bipolar Disorder (I or II, most recent episode must be depression * Failed at least 2 anti-depressant treatments and no ECT in past 6 months * Age between 18-55 years * BMI \< 35 * Hamilton Rating Scale for Depression (HSRD) score \> 18 * Quick Inventory of Depression Scale (QIDS) score \> 10.

Exclusion criteria

* • Diagnosis of primary psychotic disorder, dysthymia, or personality disorder * Significant pre-morbid cognitive impairment * Hypertension and current use of ACE inhibitor or AR blocker medications * Symptomatic coronary artery disease or congestive heart failure * History of transient ischemic or neurologic signs during the past year * History of or susceptibility to malignant hyperthermia * Contraindication to isoflurane or propofol anesthesia (as determined by anesthesiologist) * Diabetes requiring insulin * Poor kidney function * Chronic use of benzodiazepines or opioids * Individuals incompetent to provide consent (e.g. catatonic, psychotic).

Design outcomes

Primary

MeasureTime frame
Hamilton Rating Scale for Depression3 weeks

Secondary

MeasureTime frame
Quick Inventory of Depressive Symptoms3 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026